260 related articles for article (PubMed ID: 17980928)
1. Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies.
Davies M; Sinnassamy P; Storms F; Gomis R;
Diabetes Res Clin Pract; 2008 Feb; 79(2):368-75. PubMed ID: 17980928
[TBL] [Abstract][Full Text] [Related]
2. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.
Davies M; Lavalle-González F; Storms F; Gomis R;
Diabetes Obes Metab; 2008 May; 10(5):387-99. PubMed ID: 18355327
[TBL] [Abstract][Full Text] [Related]
3. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
Janka HU; Plewe G; Busch K
J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
[TBL] [Abstract][Full Text] [Related]
4. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
5. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
[TBL] [Abstract][Full Text] [Related]
6. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
Janka HU; Plewe G; Riddle MC; Kliebe-Frisch C; Schweitzer MA; Yki-Järvinen H
Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775
[TBL] [Abstract][Full Text] [Related]
7. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.
Davies M; Evans R; Storms F; Gomis R; Khunti K
Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Basal Insulin-Based Treatment Versus Twice-Daily Premixed Insulin After Short-Term Intensive Insulin Therapy in Patients with Type 2 Diabetes Mellitus in China: Study Protocol for a Randomized Controlled Trial (BEYOND V).
Liu J; Jiang X; Xu B; Wang G; Cui N; Zhang X; Liu J; Mu Y; Guo L
Adv Ther; 2020 Apr; 37(4):1675-1687. PubMed ID: 32130661
[TBL] [Abstract][Full Text] [Related]
9. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
Ilag LL; Kerr L; Malone JK; Tan MH
Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
[TBL] [Abstract][Full Text] [Related]
10. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
Jacober SJ; Scism-Bacon JL; Zagar AJ
Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
[TBL] [Abstract][Full Text] [Related]
11. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with Type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot Study.
Schiel R; Müller UA
Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):58-64. PubMed ID: 17973208
[TBL] [Abstract][Full Text] [Related]
13. Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study.
Zhang B; Zhao J; Yang W;
Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 27667797
[TBL] [Abstract][Full Text] [Related]
14. Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design.
Levin PA; Zhang Q; Mersey JH; Lee FY; Bromberger LA; Bhushan M; Bhushan R
Clin Ther; 2011 Jul; 33(7):841-50. PubMed ID: 21719107
[TBL] [Abstract][Full Text] [Related]
15. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
[TBL] [Abstract][Full Text] [Related]
16. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
Banerji MA; Baron MA; Gao L; Blonde L
Postgrad Med; 2014 May; 126(3):111-25. PubMed ID: 24918797
[TBL] [Abstract][Full Text] [Related]
17. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
[TBL] [Abstract][Full Text] [Related]
18. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Physician-Led Versus Patient-Led Titration of Insulin Glargine in Indian Patients with Type 2 Diabetes Mellitus: A Subanalysis of the Asian Treat to Target Lantus Study (ATLAS).
Misra A; Patel M; Agarwal P; Lodha S; Tandon N; Magdum M; Yajnik C; Ghosh R; Walekar A
Diabetes Technol Ther; 2019 Nov; 21(11):656-664. PubMed ID: 31335198
[No Abstract] [Full Text] [Related]
20. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
